NYSE · EBS
Emergent BioSolutions Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EBS: Nov 02, 2026
Emergent BioSolutions Inc. Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.45. The reported EPS for the same quarter last year was $1.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 27, 6:10 AM EDTSwedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue EstimatesSwedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of +14.52% and +4.09%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 6, 4:07 AM EDTEmergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · Sep 1, 10:35 AM EDTEmergent BioSolutions Secures $24M Contract Modification For CYFENDUS Anthrax Vaccine(RTTNews) – Emergent BioSolutions Inc. (EBS) announced it has received a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
- The Motley Fool · Aug 12, 6:13 PM EDTEmergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 8, 1:03 AM EDTEmergent Biosolutions Q2 Earnings Call Highlights3 Small-Cap Stocks to Watch After the Fed’s Rate CutsEmergent Biosolutions (NYSE:EBS) reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The
- RTTNews · Aug 7, 11:45 AM EDTWeekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data(RTTNews) – This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening
- RTTNews · Aug 7, 5:22 AM EDTEmergent BioSolutions Q2 Revenue Jumps, Net Loss Widens Amid Restructuring(RTTNews) – Emergent BioSolutions Inc. (EBS), a life sciences company focused on public health preparedness and medical countermeasures, reported financial results for the second quarter ended June 30, 2026.
- BNK Invest · Aug 6, 7:24 PM EDTEmergent BioSolutions is Now Oversold (EBS)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- The Motley Fool · May 1, 12:26 PM EDTEmergent (EBS) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Apr 30, 8:24 AM EDTEmergent BioSolutions Secures Singapore Health Sciences Authority Approval For Expanded ACAM2000 Use(RTTNews) – Thursday, Emergent BioSolutions Inc. (EBS) announced that Singapore's Health Sciences Authority has approved an expanded indication for ACAM2000 to include prevention of mpox disease in adults determined to be at high risk for mpox infection.
- The Motley Fool · Apr 22, 6:05 PM EDTEmergent (EBS) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Mar 27, 12:07 AM EDTEmergent BioSolutions (EBS) Price Target Decreased by 11.11% to 12.24The average one-year price target for Emergent BioSolutions (NYSE:EBS) has been revised to $12.24 / share. This is a decrease of 11.11% from the prior estimate of $13.77 dated February 21, 2026. The price target is an average of many targets provided by analys
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Emergent BioSolutions Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.